Literature DB >> 21984125

Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation.

Jeong-Gu Kang1, Vladimir Majerciak, Thomas S Uldrick, Xiaohong Wang, Michael Kruhlak, Robert Yarchoan, Zhi-Ming Zheng.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a viral interleukin 6 (vIL-6) that mimics many activities of human IL-6 (hIL-6). Both vIL-6 and hIL-6 play important roles in stimulating the proliferation of tumours caused by KSHV. Here, we provide evidence that a miRNA pathway is involved in regulation of vIL-6 and hIL-6 expression through binding sites in their open reading frames (ORFs). We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or hIL-6 in KSHV-infected cells could be enhanced by transfection of the respective miRNA inhibitors. In situ hybridization of human lymph node sections revealed that miR-1293 is primarily expressed in the germinal centre but is deficient in the mantle zone of lymph nodes, where the expression of vIL-6 is often found in patients with KSHV-associated multicentric Castleman's disease, providing evidence of an anatomical correlation. Taking these factors together, our study indicates that IL-6 expression can be regulated by miRNA interactions in its ORF and provides evidence for the role of these interactions in the pathogenesis of KSHV-associated diseases.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984125      PMCID: PMC3528401          DOI: 10.1002/path.2962

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  63 in total

1.  Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155.

Authors:  Rebecca L Skalsky; Mark A Samols; Karlie B Plaisance; Isaac W Boss; Alberto Riva; M Cecilia Lopez; Henry V Baker; Rolf Renne
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

2.  MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F.

Authors:  Géraldine Mathonnet; Marc R Fabian; Yuri V Svitkin; Armen Parsyan; Laurent Huck; Takayuki Murata; Stefano Biffo; William C Merrick; Edward Darzynkiewicz; Ramesh S Pillai; Witold Filipowicz; Thomas F Duchaine; Nahum Sonenberg
Journal:  Science       Date:  2007-07-26       Impact factor: 47.728

Review 3.  Argonaute proteins: key players in RNA silencing.

Authors:  Gyorgy Hutvagner; Martin J Simard
Journal:  Nat Rev Mol Cell Biol       Date:  2008-01       Impact factor: 94.444

4.  A viral microRNA functions as an orthologue of cellular miR-155.

Authors:  Eva Gottwein; Neelanjan Mukherjee; Christoph Sachse; Corina Frenzel; William H Majoros; Jen-Tsan A Chi; Ravi Braich; Muthiah Manoharan; Jürgen Soutschek; Uwe Ohler; Bryan R Cullen
Journal:  Nature       Date:  2007-12-13       Impact factor: 49.962

5.  Destabilization of interleukin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-binding protein AUF1.

Authors:  Serge Paschoud; Afzal M Dogar; Catherine Kuntz; Barbara Grisoni-Neupert; Larry Richman; Lukas C Kühn
Journal:  Mol Cell Biol       Date:  2006-09-05       Impact factor: 4.272

6.  Regulation of the germinal center response by microRNA-155.

Authors:  To-Ha Thai; Dinis Pedro Calado; Stefano Casola; K Mark Ansel; Changchun Xiao; Yingzi Xue; Andrew Murphy; David Frendewey; David Valenzuela; Jeffery L Kutok; Marc Schmidt-Supprian; Nikolaus Rajewsky; George Yancopoulos; Anjana Rao; Klaus Rajewsky
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

7.  Switching from repression to activation: microRNAs can up-regulate translation.

Authors:  Shobha Vasudevan; Yingchun Tong; Joan A Steitz
Journal:  Science       Date:  2007-11-29       Impact factor: 47.728

8.  microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells.

Authors:  Elena Vigorito; Kerry L Perks; Cei Abreu-Goodger; Sam Bunting; Zou Xiang; Susan Kohlhaas; Partha P Das; Eric A Miska; Antony Rodriguez; Allan Bradley; Kenneth G C Smith; Cristina Rada; Anton J Enright; Kai-Michael Toellner; Ian C M Maclennan; Martin Turner
Journal:  Immunity       Date:  2007-12-06       Impact factor: 31.745

9.  Requirement of bic/microRNA-155 for normal immune function.

Authors:  Antony Rodriguez; Elena Vigorito; Simon Clare; Madhuri V Warren; Philippe Couttet; Dalya R Soond; Stijn van Dongen; Russell J Grocock; Partha P Das; Eric A Miska; David Vetrie; Klaus Okkenhaug; Anton J Enright; Gordon Dougan; Martin Turner; Allan Bradley
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

10.  Interferons limit inflammatory responses by induction of tristetraprolin.

Authors:  Ines Sauer; Barbara Schaljo; Claus Vogl; Irene Gattermeier; Thomas Kolbe; Mathias Müller; Perry J Blackshear; Pavel Kovarik
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

View more
  37 in total

1.  KSHV RNA-binding protein ORF57 inhibits P-body formation to promote viral multiplication by interaction with Ago2 and GW182.

Authors:  Nishi R Sharma; Vladimir Majerciak; Michael J Kruhlak; Lulu Yu; Jeong Gu Kang; Acong Yang; Shuo Gu; Marvin J Fritzler; Zhi-Ming Zheng
Journal:  Nucleic Acids Res       Date:  2019-09-26       Impact factor: 16.971

2.  CLIP-seq to Identify KSHV ORF57-Binding RNA in Host B Cells.

Authors:  Yanping Ma; Poching Liu; Vladimir Majerciak; Jun Zhu; Zhi-Ming Zheng
Journal:  Curr Protoc Microbiol       Date:  2016-05-06

3.  CRISPR/Cas9-Mediated Knockout and In Situ Inversion of the ORF57 Gene from All Copies of the Kaposi's Sarcoma-Associated Herpesvirus Genome in BCBL-1 Cells.

Authors:  Andrew BeltCappellino; Vladimir Majerciak; Alexei Lobanov; Justin Lack; Maggie Cam; Zhi-Ming Zheng
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

4.  Association Between miR-605A>G, miR-608G>C, miR-631I>D, miR-938C>T, and miR-1302-3C>T Polymorphisms and Risk of Recurrent Implantation Failure.

Authors:  Hyun Ah Lee; Eun Hee Ahn; Hyo Geun Jang; Jung Oh Kim; Ji Hyang Kim; Yu Bin Lee; Woo Sik Lee; Nam Keun Kim
Journal:  Reprod Sci       Date:  2018-05-08       Impact factor: 3.060

Review 5.  KSHV microRNAs: Tricks of the Devil.

Authors:  Jie Qin; Wan Li; Shou-Jiang Gao; Chun Lu
Journal:  Trends Microbiol       Date:  2017-03-02       Impact factor: 17.079

6.  Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.

Authors:  Qin Yan; Xinting Ma; Chenyou Shen; Xu Cao; Ninghan Feng; Di Qin; Yi Zeng; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

7.  Influence of hypothalamic IL-6/gp130 receptor signaling on the HPA axis response to chronic stress.

Authors:  Milena Girotti; Jennifer J Donegan; David A Morilak
Journal:  Psychoneuroendocrinology       Date:  2012-12-04       Impact factor: 4.905

8.  MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma.

Authors:  Xiao-Pin Ma; Guopeng Yu; Xubo Chen; Qianyi Xiao; Zhuqing Shi; Lu-Yao Zhang; Haitao Chen; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexige Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Carly Conran; Jielin Sun; S Lilly Zheng; Jianfeng Xu; Long Yu; De-Ke Jiang
Journal:  Tumour Biol       Date:  2016-01-27

9.  Identification of miR-1293 potential target gene: TIMP-1.

Authors:  Ping Li; Yunyun Ma; Yuanyuan Wang; Tengfei Chen; Huaqi Wang; Heying Chu; Guoqiang Zhao; Guojun Zhang
Journal:  Mol Cell Biochem       Date:  2013-08-13       Impact factor: 3.396

10.  MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXRα.

Authors:  Dan Zhong; Yan Zhang; Yi-jun Zeng; Min Gao; Geng-ze Wu; Chang-Jiang Hu; Gang Huang; Feng-tian He
Journal:  Lipids Health Dis       Date:  2013-03-08       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.